Figure H-7 displays the evidence network for the network meta-analyses of our two discontinuation outcomes: all discontinuations and discontinuations due to adverse events. The diagram graphically displays the number of studies that comprise the evidence base for the analysis and indicates the number of head-to-head and MTX-controlled studies underpinning the pairwise comparisons. The number of trials and participants for each comparison with MTX are as follows: Abatacept (1 trial, N=232), Abatacept plus MTX (2 trials, N=744), Adalimumab plus MTX (1 trial, N=148), Certolizumab plus MTX (2 trials, N=1,195), Etanercept (1 trial, N=632), Etanercept plus MTX (1 trial, N=542), Infliximab plus MTX (3 trials, N=1,098), Methylprednisolone plus MTX (1 trial, N=29), Sulfasalazine (2 trials, N=206), Sulfasalazine plus MTX (2 trials, N=212), Tocilizumab (2 trials, N=792), and Tocilizumab plus MTX (2 trials, N=1,084). The number of trials and participants for the head-to-head comparisons are as follows: Abatacept versus Abatacept plus MTX (1 trial, N=235), Infliximab plus MTX versus Methylprednisolone plus MTX (1 trial, N=30), Sulfasalazine versus Sulfasalazine plus MTX (2 trials, N=210), and Tocilizumab versus Tocilizumab plus MTX (2 trials, N=1,082).

Appendix Figure H-7Network diagram for network meta-analysis: All discontinuations and discontinuations due to adverse events

MTX = methotrexate; N = number of patients

From: Appendix H, Supplementary Primary Network Meta-Analyses

Cover of Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 211.
Donahue KE, Gartlehner G, Schulman ER, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.